Dupixent and Narrowband UVB for Atopic Dermatitis

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05285839

Enrollment

Registered

2022-03-18

Start date

2022-04-19

Completion date

2024-12-15

Last updated

2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Detailed description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Interventions

DRUGDupixent

dupilumab 300mg

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female adult ≥ 18 years of age; * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * EASI score of 16 or greater, * IGA score of 3 or greater * BSA of 10% or greater,

Exclusion criteria

* Subjects with previous exposure to dupilumab. * Known or suspected hypersensitivity to dupilumab or any of its excipients. * History of photosensitivity.

Design outcomes

Primary

Measure	Time frame	Description
Investigators Global Assessment Score of score of 0 or 1	12 weeks	Proportion of subjects achieving an IGA score of 0 or 1 with at least a 2 grade improvement at week 12

Countries

United States

Contacts

Primary ContactElise Nelson

enelson@windsordermatology.com6094434500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026